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Abstract
Vaults are evolutionary highly conserved ribonucleoproteins particles with a hollow barrel-like structure. The main
component of vaults represents the 110 kDa major vault protein (MVP), whereas two minor vaults proteins
comprise the 193 kDa vault poly(ADP-ribose) polymerase (vPARP) and the 240 kDa telomerase-associated protein-1
(TEP-1). Additionally, at least one small and untranslated RNA is found as a constitutive component. MVP seems to
play an important role in the development of multidrug resistance. This particle has also been implicated in the
regulation of several cellular processes including transport mechanisms, signal transmission and immune responses.
Vaults are considered a prognostic marker for different cancer types. The level of MVP expression predicts the
clinical outcome after chemotherapy in different tumour types. Recently, new roles have been assigned to MVP
and vaults including the association with the insulin-like growth factor-1, hypoxia-inducible factor-1alpha, and the
two major DNA double-strand break repair machineries: non-homologous endjoining and homologous
recombination. Furthermore, MVP has been proposed as a useful prognostic factor associated with radiotherapy
resistance. Here, we review these novel actions of vaults and discuss a putative role of MVP and vaults in the
response to radiotherapy.
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Review
Major vault protein: an overview of structure and
composition
Vaults are ribonucleoprotein particles with a hollow bar-
rel-like structure [1] and a mass of 13 MD. In mammals,
it is composed of three proteins: MVP (104 kD), the
vault poly(adenosine diphosphate-ribose) polymerase
also known as VPARP (193 kD), and telomerase-asso-
ciated protein-1 TEP1 (240 kD), and small untranslated
RNA (vRNA) of 141 bases. MVP constitutes more than
70% of the total mass of the complex [2-4], while vARN
represents less than 5% [5]. The molecular architecture
of the rat liver vault complex was recently elucidated at
high resolution [6]. A vault consists of 2 dimers of half-
vaults, which align at their waists to form together a
barrel-like structure with the overall dimensions of 72 ×
41 × 41 nm. Each half-vault comprises 39 identical
major vault proteins (MVP), the major self-assembling
structural component (Figure 1). Interestingly, vaults
can open, the two halves can dissociate at their waists at
acidic pH, and half vaults can be exchanged to form
new vaults. Based on these features and on its large
interior volume, which may encapsulate hundreds of
proteins, recent interest in recombinant vaults derives
from nanoparticle research trying to exploit vaults as
drug delivery system [7,8].
The sequences of the 2 other proteins, which are not
part of this shell-like structure and probably reside at
the top center of the caps or within the vaults, are iden-
tified and are present also in the human genome.
VPARP presumably ribosylates substrates and TEP1 is
important for stabilization of vRNA. Molecular compo-
sition of the vault has been roughly estimated as 78-96
MVPs, eight VPARPs, two TEP1s, and at least six copies
of vRNA [9]. Both the high degree of evolutionary con-
servation and the complex structure of vault particles, as
well as its broad distribution in tissues, suggest an
important function in cellular processes [10]. Although
vaults have been proposed to play a role in drug resis-
tance, nucleocytoplasmic transport, and regulation of
signaling, a definitive function for MVP or vaults has yet
to be assigned as MVP knockout mice (MVP-/-) do not
have phenotypes consistent with these in vitro observa-
tions [11]. This suggests that even though the major
component of the vault particle is absent in MVP-/--
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mice, and vault particles are no longer detected, the
remaining components TEP1, VPARP, and vRNA might
still interact and possibly fulfill a functional role.
The human gene encoding MVP has been located in
chromosome 16 (16p11.2) [12], approximately 27 cM
proximal to the gene location of the multidrug resis-
tance protein-1 (MRP1, also designated as ABCC1) [12].
However, although both the ABCC1 and MVP maps to
the short arm of chromosome 16, they are rarely coam-
plified and are normally not located within the same
amplicon and can be switched on separately [12,13].
Analysis of the human MVP gene revealed a TATA-
less promoter, which also lacks other core-promoter ele-
ments but harbors several putative transcription factor
binding sites, including an inverted CCAAT box, a p53-
binding site, and a GC box element [14]. In silico analy-
sis identified a putative STAT-binding site that strongly
resembles an interferon-g-activated site element (GAS),
which binds preferentially to STAT1 homodimers [15].
Disruption of the STAT-binding site reduces basal MVP
promoter activity, suggesting a role of JAK/STAT signals
in the activation of MVP expression [16]. With up to
105 particles per cell, vaults are abundantly present in
many different cell types, although its expression varies
among tissues. Vaults are most numerous in macro-
phages [17,18] and epithelial cells with secretory and
excretory functions as well as cells chronically exposed
to xenobiotics such as bronchial cells and cells lining
the intestine [19]. Most of the vaults are located in the
cytoplasm, although a small fraction of these particles
apparently is also localized at or near the nuclear mem-
brane and the nuclear pore complex [20,21]. The wide-
spread of vaults in many diverse organisms and cell
types suggests that their function is essential to eukaryo-
tic cells.
Interaction Partners and Putative Functions of Vaults
The detailed insight on the structure of MVP and vaults
contrasts with the poor understanding of their endogen-
ous function. Several observations though indicate that
MVP is directly involved in major cytoplasmic signal
transduction cascades. In EGF-stimulated cells, tyrosine-
phosphorylated MVP complexes with the SH2-domain-
containing tyrosine phosphatase SHP-2 and interacts
with ras-activated downstream kinase Erk, presumably
to fine-tune the activity of the Erk-downstream target
Elk-1 [22]. But tyrosine-phosphorylated MVP also binds
to the SH2-domain of Src-kinase and downregulates
EGF-dependent ERK activation in Src overexpressing
cells [23]. Likewise MVP also binds to the tumour sup-
pressor phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) and a significant quantity of
endogenous PTEN associates with vault particles in
HeLa cells, thus suggesting a regulatory role for MVP in
the phosphoinositide 3-kinase/Akt (PI 3-kinase/Akt) sig-
naling pathway [24]. However, MVP-PTEN-interaction
might only be relevant for nuclear import of PTEN
thereby regulating the nuclear function of PTEN ([25],
see below). Eventually, the identification of the specific
growth factor-regulated MVP phosphorylation sites and
the complexed interaction partner on MVP in response
to growth factor stimulation are required to reveal a
scaffold or direct regulatory function of MVP/vaults on
these signal transduction cascades.
Likewise, a co-immunoprecipitation approach revealed
that the UV-induced phosphorylation status of MVP
affects the capacity of the constitutive photomorpho-
genic 1 ubiquitin ligase (COP1) to interact with the
transcription factor c-jun. In unstressed cells, cytoplas-
mic MVP/vault binds to and modifies COP1, presum-
ably via the other vault components. Following shuttling
into the nucleus, COP1 complexes with c-jun with high
affinity and suppresses its transcriptional activity by tar-
geting c-jun for degradation. After UV irradiation, phos-
phorylated MVP does not interact with COP1 anymore,
eventually leading to the alleviation of COP1-c-jun-
complex formation. Free c-jun subsequently drives AP-
1-controlled gene expression [26]. Negative regulation of
downstream signaling has also been identified on the
level of the hypoxia-inducible factor-1a (HIF-1). HIF-1a
and MVP-expression are increased under hypoxia.
Figure 1 Overall structure of the vault shell. One molecule of
MVP is colored in tan, and the others are colored in purple. (Left)
Side view of the ribbon representation. The whole vault shell
comprises a 78-oligomer polymer of MVP molecules. The size of the
whole particle is ~670 Å from the top to the bottom and ~400 Å in
maximum diameter. The particle has two protruding caps, two
shoulders, and a body with an invaginated waist. Two half-vaults are
associated at the waist with N-terminal domains of MVP. (Right) Top
view of the ribbon representation. The maximum diameter of the
cap is ~200 Å. The outer and the inner diameters of the cap-ring
are shown. Figure reproduced from Tanaka et al. (2009) with
permission from The American Association for the Advancement of
Science (Sciences Magazine).
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However, the stability of HIF-1a protein is enhanced to
higher extents in MVP-knockdown cells. Direct complex
formation of vaults with HIF-1a, PHDs and pVHL was
demonstrated and suggests that MVP/vault might act as
scaffold protein for ubiquitination and degradation of
HIF1a [27] and thereby affects hypoxia-regulated
expression of HIF-1a-dependent gene expression.
The generation of MVP-/--mice did not reveal any
further indications on an essential role of MVP and
vaults during embryogenesis and in the cellular pro-
cesses in tissues of adult mice under normal environ-
mental conditions. Furthermore, both embryonic stem
cells and bone marrow cells derived from MVP-/--mice
display a similar sensitivity towards classic cytostatic
agents as their wildtype counterpart cells, and normal
tissue toxicity towards doxorubicin in vivo is unchanged
in the MVP-deficient mice. Interestingly though and
unexpectedly identified, MVP and vaults are part of the
effective innate immune response and contribute to the
uptake and clearance of lung pathogens such as Pseudo-
monas aeruginosa via lipid rafts in lung epithelial cells,
and eventually resistance to lethality [28]. Furthermore,
the activation of MVP-expression by interferon g
through the JAK/STAT pathway and enhanced expres-
sion of MVP in macrophages and in dendritic cells sug-
gest a clear relationship with the immune system
[16,29]. However, despite the high abundance of MVP/
vaults in MVP-wildtype dendritic cells, no differences in
dendritic cell migration and antigen presentation and T-
cell responses could be observed in MVP-/--mice. In
human beings, a strong up-regulation of vault expres-
sion during dentritic cell culturing was observed, pro-
posing that vaults act as components in the cascade of
events regulating dentritic cell effector function [30].
Besides the activation of MVP by interferon, several
other observations indicate that MVP might be involved
in immunological responses [31]. It has been reported a
dramatic induction of vRNA expression in response to
infection with Epstein-Barr virus [32,33], and vRNA
induction has been has been suggested as playing
important roles in innate immunity [34]. This led to
speculate that vRNA/vaults could be involved in anti-
viral defence.
Finally, the hollow structure, the rapid movements, the
distinct subcellular localisation (as for example at the
nuclear membrane), and the in vitro and clinical corre-
lations with drug resistance in several types of human
cancers led to the hypothesis that vaults might represent
rather promiscuous transport vehicles [35-37].
Drug resistance: the best known role of MVP
The MVP has originally been identified as the lung
resistance protein [2]. LRP was discovered almost 20
years ago as a protein overexpressed in a multidrug-
resistant lung cancer cell line diverting cytostatic drugs
from intracellular targets and conferring multidrug resis-
tance (MDR) [19]. Several proteins have been linked to
MDR, such as the ABC-drug transporter p-Glycoprotein
(P-gp, also designated as ABCB1), members of the mul-
tidrug resistant protein family (ABCC1, ABCC2,
ABCC3), the human breast cancer resistance protein
(BCRP) and the lung-resistance protein (LRP) [36,38,39].
The LRP was initially discovered due to its high expres-
sion level in a multidrug-resistant but ABCB1-negative
lung cancer cell line [19] and has been identified in
1995 to be the human major vault protein [2]. Thereby,
a first link between the MDR and vaults was established.
MVP has been detected in 78% of 61 human cancer
cell lines, and its expression levels correlate with resis-
tance against a variety of MDR-related and unrelated
drugs [40,41]. Furthermore, upregulation of the MVP
expression level was determined in multiple human can-
cer cell lines also on treatment with anticancer agents,
including anthracyclins, etoposide and cisplatin, further
supporting a putative link between treatment sensitivity
and cellular stress adaptation to cytotoxic agent
[19,42-47], and overexpression of MVP is also frequently
observed at the early steps of resistance selection
[45,46,48,49]. Multiple preclinical studies have corrobo-
rated this link between MDR and the MVP expression
level in cancer cells, despite some contradicting studies
and the fact that the MVP knockout mouse does not
show enhanced hypersensitivity to cytostatics. However,
this might be due to differential cancer to normal cell
line treatment sensitivities or the upregulation of other
ABC-transporters or unknown mechanisms of MDR on
disruption of functional MVP [11,50].
Vaults may mediate multi-drug resistance by the
transport of drugs away from their subcellular targets,
by the extrusion from the nucleus and/or the sequestra-
tion of drugs into exocytotic vesicles. Either through
these exocytotic vesicles or pump molecules like
ABCB1, ABCC1, or breast cancer resistance protein at
the plasma membrane, the intracellular potency of these
cytotoxic agents will be reduced [51]. Alternatively, the
two vault-associated VPARP poly(adenosine dipho-
sphate-ribose) polymerase or TEP-1 may fulfil a protec-
tive function of the genome and thereby contribute to a
drug-resistance profile. Concomitant operation of sev-
eral drug resistance mechanisms may often be necessary
to cause the phenotype of MDR, and co-expression of
MVP and ABCC1 frequently occurs and associates with
increased drug resistance levels in MDR-selected
tumour cells [40]. Interestingly, up-regulation of MVP
could be linked in a series of MDR cell lines with a low
and intermediate level of drug resistance with subse-
quent up-regulation of ABCB1 leading to high levels of
drug resistance. These findings point the MVP
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expression level as a marker for low level of drug resis-
tance, which is clinically more relevant [19,45,48].
Furthermore, several studies reported that the expres-
sion of MVP is a predictive marker in several tumour
types for the response to chemotherapy [52,53].
Interestingly, human vRNAs produce several small
RNAs (svRNAs) by mechanisms different from those in
the canonical microRNA (miRNA) pathway. svRNAb
downregulates CYP3A4, a key enzyme in drug metabo-
lism. This finding contributes to understand the role of
vaults particles in drug resistance, proposing a novel
function to vRNAs that may help explain this associa-
tion [54].
A novel role for MVP: implications in radiotherapy
In recent years, several findings indicate a link between
MVP and vaults not only to drug-resistance based on its
putative drug-exporter function, but also to DNA-
damage and DNA-damage-repair. MVP transcription
and protein levels are increased in response to various
DNA-damaging agents, including ionizing radiation (IR)
[55]. Interestingly, VPARP and, to lesser extent, TEP-1-
deficient mice, have an increased incidence of carcino-
gen-induced colon tumours [56]. These findings indicate
that vaults may play a role in facilitating DNA repair
processes.
The high cytotoxicity of IR is mainly based on its abil-
ity to induce DNA double strand breaks (DSB) via gen-
eration of reactive oxygen species. DSB can be repaired
by the two major DSB repair machineries: homologous
recombination (HR) and non-homologous end joining
(NHEJ). The fact that error-free repair by HR depends
on the presence of an intact sister chromatid restricts
this pathway to occur during S and G2 phases of the
cell cycle. This is, in contrast to error-prone repair by
NHEJ which can function throughout the cell cycle and
is therefore thought to be the predominant DSB repair
pathway in mammalian cells. On the other hand, HR
represents the more interesting target to sensitize speci-
fically tumor cells to DNA damaging agents leading to
an enhanced therapeutic window.
MVP and vaults have recently been linked to both
major DSB-machineries. Ku70 and Ku80 are key pro-
teins in NHEJ, and also play a strong regulatory role in
apoptosis through Bax/Bcl-2 interactions [57,58]. The
DNA end-joining protein Ku70 inhibits apoptosis by
sequestering Bax away from the mitochondria. However,
newly synthesized Bax undergoes ubiquitination, which
negatively regulates its proapoptotic function by labeling
it for proteasomal degradation. Interestingly, ubiquiti-
nated Bax associates with Ku70, which mediates Bax
deubiquitination, simultaneously generating the active
form of Bax but sequestered away from the mitochon-
dria [57]. Low expression level of Ku70 might therefore
also result in low expression levels of Bax. On the level
of NHEJ, an inverse correlation between high MVP and
low expression levels of Ku70/80 and pro-apoptotic bax
was identified in a cohort of 160 patients with localized
cervix carcinoma. Interestingly, low Ku70/80 expression
was also associated with upregulated Bcl-2, altered p53,
and increased proliferation in this set of patients [59].
Despite the lack of mechanistic insights these data sug-
gest that overexpression of MVP and vaults might be
involved in a carcinogenic process with resultant geno-
mic instability due to suppressed NHEJ. Though
enhanced proliferative activity, subsequent tumour pro-
gression and enhanced treatment resistance requires at
the same time an upregulated apoptotic threshold,
which might be activated through the suppression of
Bax, upregulation of Bcl-2, mutated p53-status and
upregulation of the IGF-1R and downstream signalling
cascades. Eventually, only molecular dissection of the
key signal transduction cascades leading to reduced
NHEJ-activity in MVP-overexpressing and MVP-
depleted cells will elucidate the association between
MVP/vaults, NHEJ and a deregulated apoptotic thresh-
old. Moreover, MVP increases with age both in vitro
and in vivo, and that age-related upregulation of MVP
facilitates apoptosis resistance of senescent human
diploid fibroblasts based on the interaction with c-Jun-
mediated downregulation of BCL-2 [60]. Thus, MVP is
suggested to be playing an important role in the resis-
tance of senescent fibroblasts to apoptosis by modula-
tion of BCL-2 expression by JNK pathway, regulating
cellular signaling and survival and being a potential
therapeutic target for modulation of resistance to apop-
tosis implicated in aging modulation and cancer treat-
ment [61].
A novel link between the intracellular level of MVP
and homologous recombination, the second DNA-DSB-
repair machinery, has recently been identified as part of
the cellular stress response to ionizing radiation (Pre-
sented in ESTRO 29; S 51, 129 oral). MVP-depleted
tumour cells are more radiosensitive than their wildtype
cognate cells, probably due to direct interference with
homologous recombination. In comparison to control
cells, Rad51-foci are strongly reduced in irradiated but
MVP-depleted cells and thus vaults may coordinate cor-
rect HR-complex formation at the site of the DSB.
Vaults might also guarantee sufficient protein level of
Rad51 required for homologous recombination via coor-
dinated Rad51 expression. It has been reported that
MVP mediates nuclear import of PTEN and regulates
its nuclear function [24,62]. Nuclear PTEN expression is
high in untransformed cells but decreases with tumour
progression. While cytoplasmic PTEN inhibits the phos-
phoinositol-3-kinase (PI3K)/AKT pathway, nuclear
PTEN inhibits phosphorylation of MAPK and
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consequently reduces the expression of cyclin D leading
to a G0/G1 cell cycle arrest. Though, PTEN also acts as
cofactor for the transcription factor E2F1, driving
expression of RAD51. Cells deficient in PTEN have
reduced capacity of homologous recombination-depen-
dent DNA repair, most probably due to reduced levels
of RAD51. Thereby, PTEN is also important for the
maintenance of chromosomal stability reducing the inci-
dence of spontaneous double strand breaks. Interest-
ingly, loss of PTEN in tumour cells and concomitantly
reduced homologous recombination can thereby be
exploited by the inhibiton of PARP, creating a situation
of synthetic lethality [63,64]. Since MVP and vaults are
involved in nuclear import of PTEN and homologous
recombination, it will be of interest to determine
whether the MVP expression level also affects genomic
instability and sensitivity to PARP-inhibition.
Despite the fact that we have so far only limited
insights into the mechanisms how MVP and vault inter-
act with the two double strand-break repair machineries,
these results indicate that MVP and vaults may co-regu-
late correct DNA repair of spontaneous and treatment-
induced double strand breaks. Due to the barrel-like
structure vaults may act as carriers not only for toxic
agents but also for the coordinated intracellular trans-
port of DNA-repair related proteins and thereby act as
scaffold protein or shuttling vector. Otherwise, the
vaults associated proteins VPARP or TEP1 might play a
so far not-identified role for correct DNA repair, which
could only be achieved as part of an intact vaults. As
indicated above, in vitro studies revealed that gene
expression levels of MDR-related proteins increased
after fractionated irradiation. It is well known that radia-
tion treatment can induce resistance to various cytotoxic
drugs [65], although the molecular basis of this interac-
tion are complex. Irradiated cell lines showed a signifi-
cant resistance to cisplatin, doxorubicin and
bendamustine, suggesting a novel mechanism in the
appearance of MDR, which might involve a radiation-
induced increment of LRP/MVP [66].
MVP and tumour malignancies: vaults as a predictive/
prognostic marker
Numerous studies were performed to clarify the expres-
sion status of MVP in human malignancies as a predic-
tive and prognostic marker for the chemotherapy
response and patient prognosis (Table 1). These studies
mainly focused on haematological malignancies. The
results should be viewed with caution, since they will be
influenced by factors such as 1) MVP detection assays
(especially referred to gene expression), 2) number of
patients included, or 3) type of statistical analysis per-
formed (univariate vs. multivariate analysis). The quality
of MVP as a prognostic or predictive marker in this
type of malignancy is still questionable, and standardized
detection methods are needed. Nevertheless, a direct
association between MVP expression and therapy resis-
tance and prognosis in patients suffering from acute
myeloid leukaemia was identified [67-70]. A positive
correlation between MVP expression and worse patient
prognosis, therapy response, and survival rate has been
reported in acute lymphoblastic leukaemia patients
[71-73], and similar results have been described in adult
T-cell leukaemia [74,75] and multiple myeloma [76-78].
On the other hand, relatively few studies have
addressed the role of MVP in solid tumours, with con-
tradictory findings. Thus, the quality of MVP as prog-
nostic marker in ovarian carcinoma is unclear so far,
with positive [79,80] and negative [81,82] associations
reported. Result regarding to breast cancer [83,84], non-
small cell lung cancer [85,86], or different types of sar-
comas are inconclusive [87,88]. On the other hand,
MVP has been established as a reliable factor for
response to chemotherapy in bladder cancer patients
[89], melanoma [90], and determining the aggressive
phenotype of testicular germ-cell tumours [91] and glio-
blastoma [92].
With regard to a putative role of MVP in radiation
resistance, it has been reported that MVP expression is
strongly associated with local-disease free survival and
cancer-specific survival in a series of patients suffering
from squamous cell carcinoma of the oropharynx who
received primary radiotherapy with curative intent (in
univariate and multivariate analyses) [93]. Elevated MVP
expression seems to be associated with a RT-resistant
subset of patients, proposing MVP as a novel useful
prognostic marker associated with RT [93]. The under-
lying mechanisms behind this association are not well
Table 1 Clinical studies investigating the association
between MVP and therapy response and survival
Author Patients (n) Tumour Response DFS OS
Izquierdo [13] 57 Ovarian cancer Yes Yes Yes
Schadendorf [90] 71 Melanoma Yes
Ramani [95] 21 Neuroblastoma No
Dingemans [96] 36 NSCLC No No
Linn [97] 70 Breast cancer No
Uozaki [98] 60 Osteosarcoma Yes Yes
Arts [81] 115 Ovarian cancer No No No
Pohl [99] 99 Breast cancer No No No
Volm [100] 87 NSCLC Yes No
Goff [101] 29 Ovarian cancer No
Pohl [102] 68 Colorrecto No
Diestra [89] 83 Bladder cancer Yes
Harada [103] 57 NSCLC Yes
Silva [93] 78 HNSCC Yes Yes
DFS, disease-free survival; OS, overall survival; NSCLC, non-small cell lung
cancer; HNSCC, head-and-neck squamous cell carcinoma.
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defined today but might be linked to the above cited
role of MVP in DNA repair and apoptotic threshold.
The complexity but also interest in MVP as a predictive
and/or prognostic marker is also illustrated in cervical
cancer patients receiving combined radiochemotherapy
[52]. Increased MVP and IGF-1R expression levels were
related to a small cohort of cervical cancer patients with
reduced long-term local control, in patients who other-
wise achieved clinical complete response to radioche-
motherapy. High MVP expression was strongly related to
high IGF1-R expression, which is associated with chemo-
and radioresistance in localized cervical carcinoma
patients [94]. This association suggests that both proteins
need to be expressed to confer chemoradioresistance in
cervical cancer. This was further supported by a sub-
group of patients who showed low levels of MVP and
IGF1R and who presented excellent survival rates once
[52]. All of the responding patients with negative or fairly
positive (low MVP) tumours were free of local, distant or
death related disease. These results were similar to the
ones previously obtained for IGF-1R as a prognostic mar-
ker [94]. Combination analysis was performed grouping
MVP and IGF-1R expression in tumours, showing that
all responding patients with low MVP/IGF-1R tumours
were free of local disease, relapse or death related disease.
As illustrated by these studies, we are still far away to
have identified a mechanistic link between MVP expres-
sion level and treatment response, and it is still a matter
of debate in how far vaults are involved in chemo- and
radioresistance and thus might serve as predictive mar-
ker of therapy response. MVP is associated with MDR,
and several studies have recognized MVP as a negative
prognostic factor for response to chemo- and radiother-
apy and/or disease-free survival or overall survival.
Molecular, genetic, and clinical data obtained so far war-
rant further studies into the role of MVP, vaults-related
resistance mechanisms.
Conclusions
Vaults are ubiquitous ribonucleoprotein complexes
involved in a diversity of cellular processes, including
multidrug resistance, transport mechanisms, signal
transmission and immune response. Nonetheless, new
roles have been assigned to MVP in the field of radio-
therapy, where vaults have been proposed as a useful
prognostic marker associated with radiotherapy resis-
tance. The molecular mechanisms behind this relevant
role are unknown, although a possible association with
relevant key players in non-homologous endjoining
repair and homologous recombination could exist. Addi-
tional translational and clinical studies are required to
test this hypothesis.
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